Vernalis Research: Difference between revisions
CSV import |
CSV import |
||
| Line 32: | Line 32: | ||
[[Category:Pharmaceutical companies of the United Kingdom]] | [[Category:Pharmaceutical companies of the United Kingdom]] | ||
[[Category:Biotechnology companies]] | [[Category:Biotechnology companies]] | ||
<gallery> | |||
File:Vernalis_Research_-_A_Ligand_Company.png|Vernalis Research - A Ligand Company | |||
</gallery> | |||
Latest revision as of 22:17, 16 February 2025
Vernalis Research[edit]

Vernalis Research is a pharmaceutical company that specializes in drug discovery and development. It is known for its work in the field of structure-based drug design and has a focus on oncology, central nervous system disorders, and anti-infectives.
History[edit]
Vernalis Research was originally established as a biotechnology company in the United Kingdom. Over the years, it has evolved through various mergers and acquisitions, expanding its capabilities and research focus. The company has collaborated with numerous pharmaceutical and biotechnology firms to advance its drug discovery programs.
Research and Development[edit]
Vernalis Research employs a range of advanced technologies in its drug discovery efforts, including fragment-based drug discovery and structure-based drug design. These techniques allow the company to identify and optimize small molecules that can modulate the activity of specific biological targets. The company has developed a number of drug candidates that have progressed into clinical trials.
Collaborations and Partnerships[edit]
Vernalis Research has established partnerships with several major pharmaceutical companies to leverage its drug discovery expertise. These collaborations have resulted in the development of novel therapeutics across various therapeutic areas. The company continues to seek new partnerships to expand its research capabilities and bring innovative treatments to market.
Acquisition by Ligand Pharmaceuticals[edit]
In 2018, Vernalis Research was acquired by Ligand Pharmaceuticals, a company known for its portfolio of royalty-generating assets and drug discovery technologies. This acquisition has allowed Vernalis to further enhance its research capabilities and expand its pipeline of drug candidates.
Related pages[edit]
References[edit]
<references group="" responsive="1"></references>
-
Vernalis Research - A Ligand Company